Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
PaperCitations, authors & open-access status
Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 59 citations, 2021 year and gold oa status.
59
Citations
2021
Year
gold
OA Status